- Home
- Publications
- Publication Search
- Publication Details
Title
The Development of BTK Inhibitors: A Five-Year Update
Authors
Keywords
-
Journal
MOLECULES
Volume 26, Issue 23, Pages 7411
Publisher
MDPI AG
Online
2021-12-07
DOI
10.3390/molecules26237411
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- BTK blockers make headway in multiple sclerosis
- (2021) Elie Dolgin NATURE BIOTECHNOLOGY
- A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects
- (2021) Ehsanollah Esfandiari et al. CTS-Clinical and Translational Science
- Orelabrutinib: First Approval
- (2021) Sohita Dhillon DRUGS
- Emerging small-molecule inhibitors of the Bruton’s Tyrosine Kinase (BTK): current development
- (2021) Jiakuo Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel synthetic drugs for the treatment of non-Hodgkin lymphoma
- (2021) Farheen Manji et al. EXPERT OPINION ON PHARMACOTHERAPY
- Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
- (2021) H. Yesid Estupiñán et al. Frontiers in Cell and Developmental Biology
- Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors
- (2021) Brian T. Hopkins et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma
- (2021) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
- (2021) Chiara Brullo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design
- (2021) Mark Sabat et al. JOURNAL OF MEDICINAL CHEMISTRY
- Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
- (2021) Datong Zhang et al. MOLECULES
- Discovery of novel BTK PROTACs for B-Cell lymphomas
- (2021) Yunpeng Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase
- (2021) Dandan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2020) Daniela Angst et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants
- (2020) Ian M. Catlett et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte)
- (2020) Elise A. Chong et al. CLINICAL CANCER RESEARCH
- Tirabrutinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors
- (2020) Vincent Sibaud et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold
- (2020) Yu Teng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity
- (2020) James J. Crawford et al. ACS Medicinal Chemistry Letters
- Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes
- (2020) Jian Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome
- (2020) Radek Jorda et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bruton’s tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis
- (2020) Edgar Carnero Contentti et al. EXPERT OPINION ON EMERGING DRUGS
- Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity
- (2020) Hyewon Cho et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer
- (2020) Yuping Zhao et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- 1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase
- (2020) Soňa Krajčovičová et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- New Insights on Fak and Fak Inhibitors
- (2020) Chiara Brullo et al. CURRENT MEDICINAL CHEMISTRY
- Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)
- (2019) Scott H. Watterson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
- (2019) Yifan Feng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation
- (2019) Francisco Lopez-Tapia et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis
- (2019) Chufeng Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors
- (2019) Hong Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
- (2019) Philipp Haselmayer et al. JOURNAL OF IMMUNOLOGY
- Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors
- (2019) Zheng Zhai et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis
- (2019) Xia Yao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities
- (2019) Yue Su et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines
- (2019) Xiaofeng Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
- (2019) Richard D. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design of Potent and Selective Covalent Inhibitors of Bruton’s Tyrosine Kinase Targeting an Inactive Conformation
- (2019) Robert Pulz et al. ACS Medicinal Chemistry Letters
- Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors
- (2019) Jing Ren et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors
- (2018) Nan Zheng et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines
- (2018) Changyuan Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors
- (2018) Wataru Kawahata et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis and biological evaluation of 7 H -pyrrolo[2,3- d ]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis
- (2018) Linhong He et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors
- (2018) Yu Xue et al. JOURNAL OF MEDICINAL CHEMISTRY
- ABBV-105, a selective and irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), is efficacious in multiple preclinical models of inflammation
- (2018) Christian Goess et al. Modern Rheumatology
- Design and Synthesis of Novel 3-(2-Aminopyridin-3-yl)-1,2,4-Triazolo[4,3-b ]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors
- (2018) Chi Hoon Park et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series
- (2018) Qingjie Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk
- (2018) Richard Caldwell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis
- (2018) Wataru Kawahata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors
- (2018) Nan Zheng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ
- (2018) Linyi Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N -(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-( tert -butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor
- (2017) Qianmao Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines
- (2017) Dan Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors
- (2017) Beilei Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
- (2017) He Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads
- (2017) Qiumeng Zhang et al. MOLECULES
- Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
- (2017) Xiaojing Wang et al. ACS Medicinal Chemistry Letters
- Discovery of new BTK inhibitors with B cell suppression activity bearing a 4,6-substituted thieno[3,2-d]pyrimidine scaffold
- (2017) Qiumeng Zhang et al. RSC Advances
- Design and Synthesis of Novel Pyrazolo[3,4-d]pyrimidin-1-yl piperidine Derivatives as Bruton's Tyrosine Kinase Inhibitors
- (2017) Hyebin Park et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors
- (2016) Zhendong Song et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability
- (2016) Wendy B. Young et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
- (2016) George V. De Lucca et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
- (2016) Scott H. Watterson et al. JOURNAL OF MEDICINAL CHEMISTRY
- SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
- (2015) P.F. Smith et al. ANNALS OF THE RHEUMATIC DISEASES
- Potent and selective Bruton’s tyrosine kinase inhibitors: Discovery of GDC-0834
- (2015) Wendy B. Young et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton’s tyrosine kinase (BTK) and Janus kinase 2 (JAK2)
- (2015) Qingjie Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc Receptor-Induced Signaling and Phagocytosis
- (2014) J. Jongstra-Bilen et al. JOURNAL OF IMMUNOLOGY
- Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
- (2014) Yan Lou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prodrugs - An Efficient Way to Breach Delivery and Targeting Barriers
- (2011) Kristiina M. Huttunen et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- (2010) Julie A Di Paolo et al. Nature Chemical Biology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now